OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Rotkowitz Defines Personalized Medicine

July 23rd 2012

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, Defines Personalized Medicine

Joseph Unger on Low-Income Clinical Trial Participation

July 20th 2012

Joseph Unger, from the SWOG Statistical Center at the Fred Hutchinson Cancer Research Center, on Low-Income Clinical Trial Participation.

Dr. Gralla on Future Advances in CINV Prevention

July 20th 2012

Dr. Richard Gralla, from Quality of Life Research Associates, on Future Advances in chemotherapy-induced nausea and vomiting Prevention

Carrie Stricker on Barriers to Adopting Triple Therapy

July 19th 2012

Carrie Stricker, PhD, RN, from Abramson Cancer Center, on Barriers to Adopting Triple Therapy

Dr. Grunberg on Barriers to Effective Supportive Care

July 19th 2012

Steven M. Grunberg, MD, University of Vermont, on Barriers to Providing Effective Supportive Care for Patients with Cancer.

Dr. Bast Discusses Biomarkers for Ovarian Cancer

July 19th 2012

Dr. Robert Bast, from the MD Anderson Cancer Center, Discusses New Biomarker Panels for Ovarian Cancer Screening.

Dr. Hesketh on Barriers to MASCC Guideline Compliance

July 19th 2012

Paul J. Hesketh, MD, from Lahey Clinic Medical Center, on Barriers to Multinational Association of Supportive Care in Cancer Guideline Compliance

Dr. Yuan on Tivantinib for Hepatocellular Carcinoma

July 18th 2012

Dr. RuiRong Yuan, from Daiichi Sankyo, on the Efficacy of Tivantinib for Patietns With Hepatocellular Carcinoma.

Dr. Taplin on Abiraterone Acetate's Mechanism of Action

July 17th 2012

Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Abiraterone Acetate's Mechanism of Action

Dr. Anthony on Targeted Therapy Associated Diarrhea

July 16th 2012

Dr. Lowell Anthony from the University of Kentucky Markey Cancer Center on Targeted Therapy Associated Diarrhea.

Heidi Donovan Discusses Prioritizing Symptoms

July 13th 2012

Heidi Donovan from the University of Pittsburgh School of Nursing Discusses Prioritizing Symptoms

Dr. Concepcion Discusses Urologists Treating Cancer

July 12th 2012

Dr. Raoul Concepcion, from Urology Associates, PC, Discusses Urologists Treating Cancer.

Dr. Ryan on Neoadjuvant Abiraterone Acetate

July 11th 2012

Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses Neoadjuvant Abiraterone Acetate

Dr. Fong Discusses Immune Response to Sipuleucel-T

July 10th 2012

Dr. Lawrence Fong from University of California, San Francisco, Discusses Immune Response to Sipuleucel-T

Paul Jacobsen Discusses Survivorship Rehabilitation

July 9th 2012

Paul Jacobsen, from H. Lee Moffitt Cancer Center and Research Institute, Discusses Cancer Survivorship Rehabilitation.

Dr. Kris on the Combination of Targeted Therapies

July 6th 2012

Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, on the Combination of Molecularly Targeted Therapies.

Dr. Lichtman Discusses Supportive and Palliative Care

July 5th 2012

Dr. Stuart Lichtman, from Memorial Sloan-Kettering Cancer Center Commack, Explains the Benefits of Supportive and Palliative Care.

Donna Berry on Compliance to Oral Cancer Therapies

July 3rd 2012

Donna Berry, from Dana-Farber Cancer Institute, on Compliance to Oral Cancer Therapies.

Dr. Shore on the Enzalutamide Mechanism of Action

June 28th 2012

Neal D. Shore, MD, Managing Partner, Atlantic Urology Clinics, Director, CPI, Carolina Urologic Research Center, discusses enzalutamide, a well tolerated oral therapy.

Erin McMenamin on Head and Neck Cancer Treatments

June 28th 2012

Erin McMenamin, MSN, Radiation Oncology, Hospital of the University of Pennsylvania, discusses treatments for HPV-positive head and neck cancer, which tends to have a better prognosis than HPV-negative head and neck cancers.